drugset

drugset / Trial / NCT00584584

An Exploratory Study of the Effects of a Single Dose of QAX576 (an Interleukin-13 Monoclonal Antibody) on Simulated Hayfever

NCT00584584 ↗

Phase 2 Completed 36 enrolled Novartis

RandomizedParallel-groupDouble-blindTreatment

Summary

This study will investigate whether a single dose QAX576 (an interleukin-13 monoclonal antibody) gives protection against a model of hayfever

Timeline

Start: 2007-12
Primary completion: 2008-08
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	QAX576	Monoclonal antibody	—	—

Indications